Recognition:

To the agencies and entities that supported us, we are proud to deliver the next generation of PCR diagnostics.

At Visby Medical, we humbly believe our new diagnostic platform will become the gold standard among PCR point-of-care devices, by delivering accurate results in under 30 minutes to empower clinicians with data-driven results, while with their patient.

    February 2, 2021: Visby receives a $12.3 million award from BARDA to speed development of its rapid, single-use Flu-COVID PCR Test.

    Read more

    November 23, 2020: Visby Medical Sexual Health Click Test clinical study, sponsored by NIH/NIAID, is published in The Lancet: “Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study.”

    Read more

    October 6, 2020: Visby receives $10 Million from the NIH as part of its Rapid Acceleration of Diagnostics (RADx) initiative.

    Read more

    August 5, 2020: Visby Medical selected as the ONLY winner of $19 Million in the Antimicrobial Resistance (AMR) Diagnostic Challenge (co-sponsored by BARDA and the NIH).

    Read more